Roquefort Therapeutics (LSE:ROQ) Interest Expense : £0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Roquefort Therapeutics's interest expense for the six months ended in Dec. 2023 was £ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Roquefort Therapeutics's Operating Income for the six months ended in Dec. 2023 was £ -1.76 Mil. Roquefort Therapeutics's Interest Expense for the six months ended in Dec. 2023 was £ 0.00 Mil. Roquefort Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Roquefort Therapeutics Interest Expense Historical Data

The historical data trend for Roquefort Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Interest Expense Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Interest Expense

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Interest Expense	-	-	-	-	-

Roquefort Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Roquefort Therapeutics (LSE:ROQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Roquefort Therapeutics's Interest Expense for the six months ended in Dec. 2023 was £0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was £-1.76 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was £0.00 Mil.

Roquefort Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Roquefort Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Roquefort Therapeutics PLC has no debt.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines